PegBio Co

PegBio Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of PegBio Co (2565.HK) as of Nov 18, 2026 is 72.90 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 64.78 % — a change of 12.53% (higher).

Cash Conversion

72.90 %

YoY

12.53%

Last updated:

Cash Conversion Rate (OCF/Net Income) of PegBio Co is 2025 72.90 % . Cash Conversion Rate (OCF/Net Income) of PegBio Co was 2024 64.78 % . It decreases by 12.53% higher compared to the previous year.

The PegBio Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2022
55.93 CNY
Jan 1, 2023
83.61 CNY
Jan 1, 2024
64.78 CNY
Jan 1, 2025
72.90 CNY
The PegBio Co Cash Conversion history
YEARCash ConversionYoY
72.90 %+12.53%
64.78 %-22.52%
83.61 %+49.51%
55.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Cash Conversion Rate (OCF/Net Income) of PegBio Co is 72.90 % in 2025.

Cash Conversion Rate (OCF/Net Income) of PegBio Co changed from 64.78 % to 72.90 %, representing a 12.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s PegBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PegBio Co

All Key Metrics — PegBio Co